Skip to main content

Table 2 Cerivcogenital HPV prevalence by genotype group and relative risk by vaccination status

From: Trends in HPV cervical and seroprevalence and associations between oral and genital infection and serum antibodies in NHANES 2003–2012

 

Unvaccinated

Vaccinated

Relative risk

Age

Genotypes

N

% +

S.E.

N

% +

S.E.

RR

95 % CI

 

All

244

17.5

2.7

233

20.1

3.5

1.1

0.7–1.8

14–17

Group 1

244

12.4

2.7

233

11.2

2.9

0.9

0.5–1.8

 

6, 11, 16, 18

244

4.5

1.7

233

1.0

0.5

0.2

0.1–0.8

 

All

448

57.7

3.4

241

56.9

3.5

1.0

0.8–1.2

18–24

Group 1

448

38.8

3.5

241

30.9

3.5

0.8

0.6–1.1

 

6, 11, 16, 18

448

16.6

2.5

241

2.5

0.7

0.2

0.1–0.3

  1. Prevalence is by all, oncogenic (Group 1 genotypes), and vaccine genotypes for women ages 14–17 and 18–24 in 2009–12. Here, %+ denotes the weighted cervicogenital HPV prevalence of the listed genotypes among the N people in the population. Bold relative risks intervals do not contain 1
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us